Osaic Holdings
GLUE icon

Osaic Holdings’s Monte Rosa Therapeutics GLUE Stock Holding History

Osaic Holdings’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.2K Sell
1,594
-1,824
-53% -$34.9K ﹤0.01% 5687
2025
Q4 		$53.6K Buy
3,418
+933
+38% +$12.6K ﹤0.01% 5184
2025
Q3 		$15.3K Buy
2,485
+201
+9% +$1.06K ﹤0.01% 6108
2025
Q2 		$10.3K Buy
2,284
+1,126
+97% +$5.02K ﹤0.01% 6127
2025
Q1 		$5.37K Sell
1,158
-2,699
-70% -$16.6K ﹤0.01% 6136
2024
Q4 		$26.8K Buy
3,857
+2,799
+265% +$21K ﹤0.01% 5132
2024
Q3 		$5.61K Buy
1,058
+12
+1% +$61 ﹤0.01% 6144
2024
Q2 		$3.91K Buy
1,046
+646
+162% +$3.29K ﹤0.01% 6292
2024
Q1 		$2.82K Hold
400
– – ﹤0.01% 6333
2023
Q4 		$2.26K Buy
+400
New +$1.57K ﹤0.01% 6499

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Osaic Holdings's GLUE Position: Q1 2026 in Review

Osaic Holdings reduced its Monte Rosa Therapeutics (GLUE) stake by 53% in Q1 2026, selling an estimated $34.9K and leaving 1,594 shares worth $26.2K. The position accounts for ﹤0.01% of the portfolio, ranked #5687.

Osaic Holdings first reported a position in GLUE in Q4 2023 and has held it in 10 quarters since. The position peaked at $53.6K in Q4 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Osaic Holdings held 1,594 shares of Monte Rosa Therapeutics worth $26.2K as of Q1 2026.
  • Osaic Holdings sold 1,824 Monte Rosa Therapeutics shares in Q1 2026, an estimated $34.9K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q1 2026, its #5687 holding.
  • Osaic Holdings first reported a position in Monte Rosa Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Osaic Holdings's Monte Rosa Therapeutics position peaked at $53.6K in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Osaic Holdings's 13F filing for Q1 2026, filed 15 May 2026.